Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 10, 2015, Pages 949-960

  Tseng, T C ^a,b   Liu, C J ^c,d   Chen, C L ^d   Yang, W T ^c,e   Yang, H C ^c   Su, T H ^c,f   Wang, C C ^a,e   Kuo, S F T ^f   Liu, C H ^c,d   Chen, P J ^c,d   Chen, D S ^c,d   Kao, J H ^c,d  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HUMAN; LIFESPAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RISK ASSESSMENT; STOP CODON; VIRUS CARRIER; BLOOD; COHORT ANALYSIS; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HETEROZYGOTE; INCIDENCE; VIROLOGY;

ADULT; AGED; CARRIER STATE; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 84927747510     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13170     Document Type: Article

References (47)

1. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Chen DS,. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011; 54: 381-92.
3. Liu J, Yang HI, Lee MH, et al,. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-82.
4. Tseng TC, Kao JH,. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013; 48: 13-21.
5. Chu CM, Liaw YF,. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-92.
6. Tseng TC, Liu CJ, Yang HC, et al,. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-9 e3; quiz e13-4.
7. Tseng TC, Liu CJ, Su TH, et al,. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-25 e2.
8. Tseng TC, Liu CJ, Yang HC, et al,. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55: 68-76.
9. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
10. Kao JH, Chen PJ, Lai MY, Chen DS,. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
11. Kao JH, Chen PJ, Lai MY, Chen DS,. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-34.
12. Yang HI, Yeh SH, Chen PJ, et al,. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-43.
13. Tseng TC, Liu CJ, Yang HC, et al,. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015; 64: 292-302.
14. Tseng TC, Liu CJ, Yang HC, et al,. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57: 441-50.
15. Tseng TC, Liu CJ, Chen CL, et al,. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 2013; 208: 584-93.
16. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
17. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
18. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
19. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
20. Chiu YC, Liao SF, Wu JF, et al,. Factors affecting the natural decay of hepatitis B surface antigen in children with chronic hepatitis B virus infection during long-term follow-up. J Pediatr 2014; 165: 767-72 e1.
21. Tseng TC, Liu CJ, Chen CL, et al,. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012; 205: 54-63.
22. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
23. Tseng TC, Liu CJ, Yang WT, et al,. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. J Gastroenterol Hepatol 2014; 29: 1242-9.
24. Yeh SH, Tsai CY, Kao JH, et al,. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41: 659-66.
25. Liu SF, Hsieh MH, Hou NJ, et al,. Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. Hepatol Int 2010; 4: 601-7.
26. Tseng TC, Liu CJ, Su TH, et al,. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012; 206: 1521-31.
27. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL,. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986; 18: 301-7.
28. Yuen MF, Wong DK, Sablon E, et al,. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-701.
29. Liu J, Lee MH, Batrla-Utermann R, et al,. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013; 58: 853-60.
30. Chu CJ, Hussain M, Lok AS,. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-62.
31. Wong GL, Chan HL, Yiu KK, et al,. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 517-26.
32. Liu CJ, Cheng HR, Chen CL, et al,. Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. J Viral Hepat 2011; 18: e482-90.
33. Chu CM, Liaw YF,. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-65.
34. Maini MK, Boni C, Lee CK, et al,. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-80.
35. Cheng HR, Liu CJ, Tseng TC, et al,. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS ONE 2013; 8: e53008.
36. Kamatani Y, Wattanapokayakit S, Ochi H, et al,. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-5.
37. Seto WK, Wong DK, Kopaniszen M, et al,. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-703.
38. Brouwer WP, Sonneveld MJ, Tabak F, et al,. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2014; 40: 811-8.
39. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS,. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
40. Marcellin P, Bonino F, Lau GK, et al,. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79 e1-4.
41. Wang HY, Chien MH, Huang HP, et al,. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 2010; 84: 3454-63.
42. Liu CJ, Chen TC, Chen PJ, et al,. Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: comparison of genotypes B and C at various immune stages. J Gastroenterol Hepatol 2015; 30: 172-7.
43. Liu CJ, Chen PJ, Lai MY, et al,. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int 2006; 26: 949-55.
44. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS,. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-68.
45. Kao JH, Chen PJ, Lai MY, Chen DS,. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72: 363-9.
46. Ni YH, Chang MH, Wang KJ, et al,. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127: 1733-8.
47. Coffin CS, Rezaeeaval M, Pang JX, et al,. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther 2014; 40: 1262-9.